• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Biotechnology’s Role in Improving Stroke Outcomes

    CEO Spotlight: Marc Kikuchi

    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex

    Schott Creates Stand-Alone Company for its Pharma Business

    Marken to Acquire Medical Courier Business of Cedra Express

    Porton’s New Crystallization and Drug Product Facility

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Marken to Acquire Medical Courier Business of Cedra Express

    Porton’s New Crystallization and Drug Product Facility

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site

    Woodstock Sterile Solutions Fills Two Leadership Roles

    SmartLabs To Open New Facility in Philadelphia
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Marken to Acquire Medical Courier Business of Cedra Express

    5 Key Features of Agile Pharmaceutical Packaging Supply Chains That Drive Results

    Novavax Expands Manufacturing Agreement with SK bioscience

    Lonza Continues to Lead the Market with Innovative Hard Empty Capsules

    Sharp Expands Reach to China Through Partnership with ClinsChain
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site

    Thorne HealthTech, AstraZeneca Entend AI Discovery Alliance

    Gilead Sciences to Acquire MiroBio for $405M

    Amgen to Acquire ChemoCentryx for $3.7B

    BioNTech, Genmab Expand Global Strategic Oncology Collaboration
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Chime Biologics Receives Commercial Manufacturing License

    Automation Is Key to Meeting Demands in Pharmacovigilance

    UBC Acquires Examoto

    Responding to Consumer Complaints While Working with CMOs

    WuXi Vaccines Receives GMP Certificate from HPRA
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Vector Partners Limited

    Aphena Pharma Solutions

    Kyongbo Pharmaceutical

    Baxter BioPharma Solutions

    Biosynth Carbosynth
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Vector Partners Limited

    Aphena Pharma Solutions

    Kyongbo Pharmaceutical

    Baxter BioPharma Solutions

    Biosynth Carbosynth
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

    Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.

    The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs
    Related CONTENT
    • ViscoTec America Inc.
    • SGS Health Science
    • Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    • Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    • Asychem Partners with LaNova Medicines
    Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group01.07.21
    Oncology trials now make up more than one-third of today’s research pipeline, but conventional oncology development programs often are inefficient and have high failure rates. Of the oncology agents that enter Phase I trials, only about 3% eventually receive U.S. Food and Drug Administration (FDA) approval.1

    We can do better. The application of appropriate adaptive designs at the early stages of development can not only accelerate timelines and reduce costs, but also can help focus development on the most promising agents at the right doses in the right indications for the right patients.

    Adaptive designs potentially allow a trial to answer multiple questions at once, leveraging accumulating data so early findings can inform decisions in a flexible process. In contrast, traditional designs answer only one narrow scientific question at a time on a rigid sequential path in which answers to pivotal research questions are often obtained only at the end of the trial.

    Our experience in submitting protocols with adaptive designs in early stage oncology trials to U.S. and European regulators is that they not only accept these designs – they actively encourage them.

    Given that the methods are more efficient, well established and that regulators encourage their use – both through published guidance and in practice – why has adoption not occurred more quickly? To examine the question, let’s explore a specific example.

    Defining the maximum tolerated dose (MTD)
    Defining an accurate dose in early-phase oncology clinical trials is a common challenge. The MTD is estimated to be correct in only about 40% of trials,2 which may result in patients in subsequent trials being treated at subtherapeutic doses or doses that are too toxic. Selection of the wrong dose can not only disrupt the outcomes of all subsequent phases, it can, without a correction, ultimately lead to the development program’s failure.

    Most trials still identify MTD using the 3+3 design, a rule-based design that offers simplicity, convenience and familiarity. However, 3+3 has significant limitations. It relies on fixed cohort sizes, ignoring uncertainties, to define an MTD based only on data from the last dose. It also offers no ability to re-escalate or respond when late toxicities emerge. Several improved rule-based dose escalation designs have gained popularity in recent years, including the modified toxicity probability interval (mTPI) design and Bayesian optimal interval (BOIN) design.

    The continual reassessment model (CRM), an adaptive Bayesian model-based approach introduced in 1990, efficiently evaluates more doses – using all the data it collects – to estimate the MTD more precisely and with more confidence compared to 3+3 and other rule-based designs. The difference in accuracy becomes more obvious as more dose levels are tested. As a result, the CRM provides an increased chance of treating study patients around the MTD and a decreased chance of exposing patients dosed at levels greater than MTD. Several variants of the CRM have been developed, including the Neuenschwander, et. al., NCRM design with overdose control, which is the most-commonly used one (also referred to as Bayesian Logistic Regression Model [BLRM]).

    Even though the CRM has been shown to be more accurate in targeting the MTD than the 3+3 design, uptake has been slow. Lack of familiarity with the model and aversion to perceived risk has deterred adoption. But, in fact, many of the barriers impeding early adoption of the CRM have now been overcome. The following chart details common misconceptions that continue to linger.

    Thirty years of CRM in practice: Early barriers to adoption have now been addressed
    Misconceptions Truths
    CRM is operationally different compared to 3+3 Operationally, CRM is very similar to 3+3
    User-friendly simulation software is not available Powerful software now enables simulation of many common dose-escalation trials (e.g., Berry Consultants’ Fixed and Adaptive Clinical Trial Simulator (FACTS™)
    Dose recommendations from a model-based design cannot be overridden by clinicians CRM only provides a dose recommendation that can be overruled by a dose escalation committee
    Incorporating the CRM design into a study synopsis or protocol will delay the study start
     
    This is potentially true, but only if the study protocol is already near final. Otherwise, simulations can be performed in parallel.
    Moreover, even if the date of first patient in (FPI) is delayed, the study completion is still likely to be sooner due to a shorter study duration.
    The CRM design is cost prohibitive By potentially requiring fewer patients and allowing for more rapid progression through early dosing levels, the CRM often, in fact, reduces costs. Bigger picture, when you consider the potential costs of taking a suboptimal dose into the next phase, it becomes clear that identifying the right MTD in the dose-escalation phase could arguably generate the greatest cost savings – and advantage – that a program could gain.
     
     
    Part of the beauty of the CRM design is that simulations can compare the performance of the CRM design to the 3+3 and other designs. In our experiences, simulations typically inspire confidence in the CRM design, and then, in turn, the CRM design in practice inspires adoption. In subsequent trials, the CRM often is selected from the start as the go-to dose escalation design.

    In our experience, the key to adopting innovative designs is simple: try them. Once you have made a foray into these new ways of working, traditional methods may strike you as inflexible, slow and unclear compared to the flexibility and efficiency inherent in adaptive designs.
     
    1Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273-286.
    2North B, Kocher HM, Sasieni P. A new pragmatic design for dose escalation in Phase 1 clinical trials using an adaptive continual reassessment method. BMC Cancer. 2019;19(1):632.


    Jürgen Hummel, MSc, is the senior director of statistical science in biostatistics at  PPD. He’s been with the company since 2006 and currently leads its statistical science track within biostatistics and provides statistical consistency both internally and externally. He has been leading PPD’s cross-departmental Adaptive Design Working Group since its inception. During his 25-year career, he has held a variety of technical and managerial positions in biostatistics, predominantly within the CRO industry.
    Related Searches
    • Clinical Trials
    • Drug Development
    Suggested For You
    ViscoTec America Inc. ViscoTec America Inc.
    SGS Health Science SGS Health Science
    Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate  Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    Asychem Partners with LaNova Medicines Asychem Partners with LaNova Medicines
    BioVaxys Reports Progress on Covid-19 Vax Candidate BioVaxys Reports Progress on Covid-19 Vax Candidate
    Syneos Health Acquires Clinical Trial Recruitment and Retention Company StudyKIK Syneos Health Acquires Clinical Trial Recruitment and Retention Company StudyKIK
    Aurion Biotech Makes Strategic Investments in Manufacturing Aurion Biotech Makes Strategic Investments in Manufacturing
    Eliminating Endotoxins – Reagent Quality Testing for Cell and Gene Therapies Eliminating Endotoxins – Reagent Quality Testing for Cell and Gene Therapies
    AbbVie, REGENXBIO Enter Eye Care Collaboration AbbVie, REGENXBIO Enter Eye Care Collaboration
    AzurRx BioPharma Acquires First Wave Bio Inc. AzurRx BioPharma Acquires First Wave Bio Inc.
    UK Govt. Terminates Valneva COVID Vax Agreement UK Govt. Terminates Valneva COVID Vax Agreement
    Eloxx Pharmaceutical Appoints Ali Hairiri as Chief Medical Officer Eloxx Pharmaceutical Appoints Ali Hairiri as Chief Medical Officer
    The Future of Clinical Trials The Future of Clinical Trials
    Planning For Better Clinical Trials Planning For Better Clinical Trials

    Related Buyers Guide Companies

    • ViscoTec America Inc.

      ...
      Melanie Hintereder, Marketing 11.05.21

    • Chemistry | Extractables and Leachables | Microbiology
      SGS Health Science

      SGS Health Science

      ...
      Jessica Martin, Marketing Director 10.26.21

    • Biologics, Proteins, Vaccines | Breaking News | Clinical Trials
      Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany

      Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany

      Covers the combination of DHODH inhibitors and nucleoside analogues to treat viral infections, including Covid-19.
      09.22.21


    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Clinical Trial Materials | Industry News
      Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate

      Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate

      Will initiate the GMP manufacturing of the clinical batches of FluGen’s M2SR influenza vaccine candidate for upcoming clinical trials.
      09.21.21

    • Breaking News | Collaborations & Alliances | Industry News
      Asychem Partners with LaNova Medicines

      Asychem Partners with LaNova Medicines

      Will provide one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration.
      09.16.21

    Loading, Please Wait..
    Trending
    • Gilead Sciences To Acquire MiroBio For $405M
    • Amgen To Acquire ChemoCentryx For $3.7B
    • BioNTech, Genmab Expand Global Strategic Oncology Collaboration
    • Bayer Opens New Research And Innovation Center At Kendall Square
    • Datwyler To Double Capacity At Production Ops In Pune
    Breaking News
    • BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex
    • Schott Creates Stand-Alone Company for its Pharma Business
    • Marken to Acquire Medical Courier Business of Cedra Express
    • Porton’s New Crystallization and Drug Product Facility
    • Thermo Fisher Expands NY Cell Culture Media Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Biotechnology’s Role in Improving Stroke Outcomes
    • CEO Spotlight: Marc Kikuchi
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    3i Solutions Announces New Leadership Positions
    INS Nutra Opens Gummy Manufacturing Facility
    Vital Nutrients Launches First Vegan Omega Supplement with SPMs
    Coatings World

    Latest Breaking News From Coatings World

    HGTV Home by Sherwin-Williams Announces 2023 Color Collection of the Year
    BASF to Produce More Specialty Pyrrolidones in North America
    Glasurit and FIVA Renew Their Partnership
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Elizabeth Coleon Joins Withings as Chief Marketing Officer
    U.K. Strengthens Medical Device Regulations
    Fujirebio Acquires ADx NeuroSciences
    Contract Pharma

    Latest Breaking News From Contract Pharma

    BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex
    Schott Creates Stand-Alone Company for its Pharma Business
    Marken to Acquire Medical Courier Business of Cedra Express
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Body Shop Expands Partnership with Uber
    COSRX Launches Vitamin E Vitalizing Sunscreen
    Weekly Recap: Kylie Makeup Lab Controversy, Glossier Pivots to Retail and Wholesale & More
    Happi

    Latest Breaking News From Happi

    Watsons China Launches Health Care Zone Prompted by the Covid-19 Pandemic
    Earth Therapeutics Celebrates National CBD Day with Foot Balm-Enriched CBD
    Diversey Europe, LG Electronics Ink Distribution Agreement in UK/Ireland
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Zeller+Gmelin, Epple Druckfarben Lead This Week’s News Stories
    A-Flex Label Adds Epson SurePress UV Digital Label Press
    Ball Announces 2Q 2022 Results
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eukalin acquires Adhesives Specialists
    EyeC unveils new inspection products
    Errol Moebius named VP of IST America
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: A New Day for Hygiene, Glatfelter Reports Q2 Results & More
    Dyper Achieves B Corp Certification
    Edgewell’s Sales Grow
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    NuVasive Inc. Reports Q2 2022 Financial Results
    Solid Growth Ahead for Carpal Tunnel Release Systems Sector
    ODT's Most-Read Stories This Week—Aug. 6
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: STMicroelectronics, NextFlex and onsemi Top This Week’s Stories
    Zebra Technologies Reports 2Q 2022 Results
    InnovationLab Demonstrates New PCB Production Method Based on Additive Manufacturing

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login